Physician profile
Daniel B Martinez
NPI 1194896878
$8,468.69
in general payments reported to CMS, 2019-2025
25 companies · $1,927 in 2025
The $1,927 reported for 2025 was more than what 93% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $294 · 2021: $195 · 2022: $1,071 · 2023: $2,677 · 2024: $1,775 · 2025: $1,927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,387 · Travel and Lodging: $887 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,387.20 |
| Travel and Lodging | $886.69 |
| Education | $105.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,151.35 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Abbvie INC. | $902.31 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $820.91 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $804.28 | 2020-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $623.76 | 2022-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $469.90 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $457.27 | 2020-2025 | Caplyta |
| Alkermes, INC. | $445.13 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $354.78 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $270.32 | 2024-2025 | Cobenfy |
| Corium, LLC | $257.14 | 2022-2025 | Azstarys |
| Lundbeck LLC | $212.14 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $170.34 | 2024-2025 | Fanapt |
| Ironshore Pharmaceuticals INC. | $143.49 | 2019-2023 | Jornay Pm |
| Axsome Therapeutics, INC. | $86.86 | 2023-2025 | Auvelity |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $64.20 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $42.74 | 2020-2022 | |
| Novo Nordisk INC | $41.96 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Tempus Ai, INC | $35.62 | 2024 | |
| Eisai INC. | $24.31 | 2020 | |
| Shire North American Group INC | $22.17 | 2019 | |
| Janssen Biotech, INC. | $19.58 | 2023 | |
| Idorsia Pharmaceuticals US INC | $19.16 | 2022 | |
| Bausch Health US, LLC | $15.77 | 2025 | Wellbutrin, Aplenzin |
| Owp Pharmaceuticals, INC. | $13.20 | 2023 | Subvenite, Lamotrigine |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.